Applied Therapeutics, Inc.

$0.10+0.00%(+$0.00)
TickerSpark Score
49/100
Weak
70
Valuation
40
Profitability
55
Growth
48
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLT research report →

52-Week Range1% of range
Low $0.09
Current $0.10
High $1.50

Companywww.appliedtherapeutics.com

Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

CEO
Les D. Funtleyder
IPO
2019
Employees
35
HQ
New York City, NY, US

Price Chart

-81.62% · this period
$1.47$0.78$0.09Feb 04Aug 06Feb 04

Valuation

Market Cap
$14.86M
P/E
-0.83
P/S
14.86
P/B
-26.72
EV/EBITDA
-0.05
Div Yield
0.00%

Profitability

Gross Margin
-2845.50%
Op Margin
-9840.30%
Net Margin
-1813.80%
ROE
-65.63%
ROIC
-5074.94%

Growth & Income

Revenue
$455.00K · -95.45%
Net Income
$-105,624,000 · 11.81%
EPS
$-0.76 · 46.48%
Op Income
$-104,299,000
FCF YoY
-52.80%

Performance & Tape

52W High
$1.50
52W Low
$0.09
50D MA
$0.15
200D MA
$0.46
Beta
2.08
Avg Volume
15.80M

Get TickerSpark's AI analysis on APLT

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 3, 26Kanter Stacy J.sell22,500
Feb 3, 26Kanter Stacy J.sell200,000
Feb 3, 26Kanter Stacy J.other42,500
Feb 3, 26Kanter Stacy J.sell16,500
Dec 19, 25Hooks Corwin Daleother312,500
Feb 3, 26Hooks Corwin Dalesell862,500
Feb 3, 26Hooks Corwin Daleother5,753
Dec 19, 25Chinoporos Constantineother437,500
Feb 3, 26Chinoporos Constantinesell1,000,000
Feb 3, 26Chinoporos Constantineother57,111

Our APLT Coverage

We haven't published any research on APLT yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate APLT Report →

Similar Companies